Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;71(1):20-24.
doi: 10.5455/medarh.2017.71.20-24. Epub 2017 Feb 5.

Prognostic Parameters of Acute Myeloid Leukaemia at Presentation

Affiliations

Prognostic Parameters of Acute Myeloid Leukaemia at Presentation

Azra Jahic et al. Med Arch. 2017 Feb.

Abstract

Introduction: The treatment response and outcome in acute myeloid leukaemia (AML) is heterogeneous.

Aim: To analyze the prognostic parameters of AML at presentation.

Methods: The total sample of 44 AML patients was analyzed on the basis of age <55 and ≥55 years, sex, WBC count <50x10/9/l and ≥50x10/9/l, the Hb concentration <100 g/l and ≥100 g/l, PLT count <100x10/9/l and ≥100x10/9/l, Karnofsky score <60% and >60%, cytogenetics, CD56 expression, morphological type and types of treatment (standard and reduced induction chemotherapy, high-dose chemotherapy/stem cell transplantation - autologous and HLA matched, related, allogeneic, together and separately).

Results: The age <55 years, Karnofsky score >60% and standard induction chemotherapy statistically correlated with the higher complete remission (CR) rates, longer relapse free survival (RFS), lower relapse rate (RR), and longer overall survival (OS) (p<0.01). The difference in terms of CR and RR between the sexes were not statistically significant (p<0.05), however women had statistically lower OS comparing to men (9.71±4.54 months vs. 38.03±9.17 months) (p<0.01). WBC count ≥ 50x10/9/l and the Hb concentration <100 g/l statistically correlated with shorter OS (p<0.05), while the WBC count ≥50x10/9/l statistically correlated with shorter RFS (p<0.05). The PLT count <100x10/9/l and ≥100x10/9/l was not found as prognostically significant for CR, RR, RFS, and OS (p<0.05). In comparison to the standard induction chemotherapy, both types of high dose chemotherapy/stem cell transplantation (HDT/SCT) (10/22), together and separately, resulted in longer RFS, lower RR, and longer OS (p<0.05). The frequency of cytogenetic risk was intermediate 81.6%, unfavorable 13.2%, and favorable 5.3%, respectively. CD56 + expression statistically correlated with the lower PLT count, higher RR, shorter RFS, and shorter OS (p<0.05). Statistical analysis of the cytogenetic risk and morphological types of AML were not possible due to the small number of patients in stratified groups.

Conclusions: Female sex, the WBC count >50x10/9/l, the concentration of Hb <100 g/l, and CD56 + expression, at presentation of AML, should be considered as parameters of adverse risk, especially in latter decisions considering post-remission treatment with HDT/SCT.

Keywords: acute myeloid leukaemia; prognosis; prognostic parameter.

PubMed Disclaimer

Conflict of interest statement

• Conflict of interest: none declared.

Figures

Figure 1
Figure 1
Correlation of age and overall survival in AMLpatients
Figrue 2
Figrue 2
Relapse free survival compared to the WBC count
Figure 3
Figure 3
Overal survival compared to the Kornofsky score
Figure 4
Figure 4
Overal survival compared to the type of treatment

Similar articles

Cited by

References

    1. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics 1997-2002. Cancer Causes Control. 2008;19:379–390. - PubMed
    1. Yin JA, O¨Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML – 15 trial. Blood. 2012;120:2826–35. - PubMed
    1. Béné MC, Bernier M, Casasnovas RO, et al. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol. 2001;113:737–45. - PubMed
    1. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84(10):937–45. - PubMed
    1. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mo¨llgård R, Stockelberg D, Tidefelt U, Wahlin A, Ho¨glund M. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87. - PubMed

MeSH terms